|
|
|
|
| LEADER |
05424nam a2200553 4500 |
| 001 |
ocn941134276 |
| 003 |
OCoLC |
| 005 |
20180501122029.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160226s2016 mau o 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d YDXCP
|d UIU
|d OPELS
|d N$T
|d IDEBK
|d CDX
|d OPELS
|d UIU
|d OCLCF
|d EBLCP
|d YDX
|d OCLCO
|d OCLCA
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 942843951
|a 945612072
|a 964291229
|a 987926073
|
| 020 |
|
|
|a 9780128052105
|q electronic bk.
|
| 020 |
|
|
|a 0128052104
|q electronic bk.
|
| 020 |
|
|
|a 9780128047941
|
| 020 |
|
|
|a 0128047941
|
| 035 |
|
|
|a (OCoLC)941134276
|z (OCoLC)942843951
|z (OCoLC)945612072
|z (OCoLC)964291229
|z (OCoLC)987926073
|
| 050 |
|
4 |
|a QH603.I54
|
| 060 |
|
4 |
|a QU 55.7
|
| 072 |
|
7 |
|a SCI
|x 056000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 571.6/4
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Ion channels as therapeutic targets.
|n Part A /
|c edited by Rossen Donev.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v volume 103
|
| 500 |
|
|
|a Includes indexes.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed March 3, 2016).
|
| 520 |
|
|
|a This volume is the second part ofïÅưthe thematic on Ion Channels as Therapeutic Targets. The popular Advances in Protein Chemistry and Structural Biology series, an essential resource for protein chemists, ïÅưbrings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.
|
| 505 |
0 |
|
|a Front Cover; Ion Channels as Therapeutic Targets, Part A; Copyright; Contents; Contributors; Preface; Chapter One: Proteostasis Maintenance of Cys-Loop Receptors; 1. Introduction; 2. Folding, Assembly, and Degradation of Cys-Loop Receptors in the ER; 2.1. Folding and Assembly of Cys-Loop Receptors; 2.2. ERAD of the Cys-Loop Receptors; 3. Trafficking of Cys-Loop Receptors from ER to Golgi and to Plasma Membrane; 4. Protein Quality Control of Cys-Loop Receptors on the Plasma Membrane; 4.1. Clustering; 4.2. Endocytosis; 5. Other Regulations of Cys-Loop Receptors
|
| 505 |
8 |
|
|a 5.1. Lipid Involvement in Trafficking and Clustering5.2. Phosphorylation Signaling in the Biogenesis of the Receptors; 6. Disease and Therapy; References; Chapter Two: Harnessing the Flow of Excitation: TRP, Voltage-Gated Na+, and Voltage-Gated Ca2+ Channels in Contemporary M ...; 1. Introduction; 1.1. Place of TRP, Nav, and Cav Channels in the Flow of Excitation in Neural Circuits; 2. TRP Channels; 2.1. Structure and Structural Varieties-Subfamilies of TRP Channels; 2.2. Regulation and Activation Mechanisms; 2.3. Therapeutic Potential of TRP Channels; 3. Voltage-Gated Na+ Channels
|
| 505 |
8 |
|
|a 3.1. Structure3.2. Inactivation of Nav Channels; 3.3. Isoforms and Expression; 3.4. Regulation of Nav Channels; 3.5. Nav Channels as Therapeutic Targets; 3.5.1. Local Anesthetics; 3.5.2. Nav Blockers as Antiarrhythmic and Antianginal Drugs; 3.5.3. Nav Blockers in Neurological Disordes; 4. Voltage-Gated Ca2+ Channels; 4.1. Structure and Function; 4.2. Varieties and Expression; 4.2.1. Cav1 Channels; 4.2.2. Cav2 Channels; 4.2.3. Cav3 Channels; 4.3. Regulation; 4.4. Calcium Channels in Pharmacological Therapy; 4.4.1. L-Type Channel Blockers; 4.4.2. Blockers and Modulators of Cav2 Channels
|
| 505 |
8 |
|
|a 4.4.3. Nonspecific Cav Channel Inhibitors5. Channelopathies of TRP, Nav, and Cav Channels; 5.1. TRP Channelopathies; 5.2. Channelopathies of Voltage-Gated Na+ Channels; 5.2.1. Nav1.1; 5.2.2. Nav1.2; 5.2.3. Nav1.4; 5.2.4. Nav1.5; 5.2.5. Nav1.6; 5.2.6. Nav1.7; 5.2.7. Nav1.8; 5.2.8. Nav1.9; 5.2.9. Nav β Subunit Channelopathies; 5.3. Channelopathies of Voltage-Gated Ca2+ Channels; 5.3.1. Cav1.1; 5.3.2. Cav1.2; 5.3.3. Cav1.3; 5.3.4. Cav1.4; 5.3.5. Cav2.1; 5.3.6. Cav3 Channels; 5.3.7. Cav Ancillary Subunit Channelopathies; 5.4. Acquired Channelopathies
|
| 505 |
8 |
|
|a 5.5. Considerations on the Treatment of Channelopathies6. Harnessing the Flow of Excitation in Neural Circuits; 7. Conclusion and Perspectives; Acknowledgments; References; Chapter Three: Ion Channels in Neurological Disorders; 1. Introduction; 1.1. Intricacy of Ion Channels in Membrane Physiology; 1.2. Role of Ion Channels in the Brain Homeostasis; 1.3. Impact of Channels on Blood-Brain Barrier; 1.4. How Channels Affect Gap Junctions, Release of Ions, and Homeostasis?; 1.5. What Are the Different Channels That Cause Ion Disturbance in Neurological Disorders?; 2. Aberrant Channels in NDDs
|
| 504 |
|
|
|a Includes bibliographical references and indexes.
|
| 650 |
|
0 |
|a Ion channels.
|
| 650 |
|
7 |
|a SCIENCE / Life Sciences / Anatomy & Physiology
|2 bisacsh
|
| 650 |
|
7 |
|a Ion channels.
|2 fast
|0 (OCoLC)fst00978573
|
| 650 |
|
2 |
|a Ion Channels.
|0 (DNLM)D007473
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Donev, Rossen
|t Ion Channels as Therapeutic Targets, Part A
|d : Elsevier Science,c2016
|z 9780128047941
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 103.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/18761623/103
|z Full Text via HEAL-Link
|
